During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.



Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.



Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.



<h3>AbbVie (NYSE:ABBV)</h3>



<ul>
<li>Dividend Yield: 3.30%</li>



<li>Piper Sandler analyst David Amsellem maintained an Overweight rating and raised the price target from $294 to $298 on May 14, 2026. This analyst has an accuracy rate of 77%</li>



<li>Guggenheim analyst Vamil Divan maintained a Buy rating with a price target of $249 on May 1, 2026. This analyst has an accuracy rate of 78%.</li>



<li>Recent News: On April 29, AbbVie reported better-than-expected first-quarter financial results.</li>



<li>Benzinga Pro’s real-time newsfeed alerted to latest ABBV news. </li>
</ul>



<figure class="wp-block-image size-full is-resized"></figure>



<h3>GSK plc (NYSE:GSK)</h3>



<ul>
<li>Dividend Yield: 3.58%</li>



<li>Barclays analyst James Gordondowngraded the stock from Equal-Weight to Underweight on Jan. 6, 2026. This analyst has an accuracy rate of 63%.</li>



<li>Jefferies analyst Michael Leuchten upgraded the stock from Hold to Buy on Oct. 27, 2025. This analyst has an accuracy rate of 63%</li>



<li>Recent News: On May 18, GSK Arexvy RSV vaccine gained Japan approval for adults 18-49 at increased risk as immunocompromised added to label.</li>



<li>Benzinga Pro's real-time newsfeed alerted to latest GSK news </li>
</ul>



<figure class="wp-block-image size-full is-resized"></figure>



<h3>Bristol-Myers Squibb Co (NYSE:BMY)</h3>



<ul>
<li>Dividend Yield: 4.40%</li>



<li>B of A Securities analyst Tim Anderson maintained a Buy rating and cut the price target from $68 to $67 on April 9, 2026. This analyst has an accuracy rate of 52%</li>



<li>Guggenheim analyst Seamus Fernandez maintained a Buy rating with a price target of $72 on April 8, 2026. This analyst has an accuracy rate of 75%.</li>



<li>Recent News: On May 12, Bristol-Myers Squibb announced a partnership with Hengrui Pharma to develop a portfolio of 13 early-stage programs spanning oncology, hematology and immunology.</li>



<li>Benzinga Pro’s real-time newsfeed alerted to latest BMY news </li>
</ul>



<figure class="wp-block-image size-full is-resized"></figure>







<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><div>
 
</div></figure>



Photo via Shutterstock

ABBV

ARKG

SBIO

PILL

In turbulent markets, investors favor high-dividend stocks. Benzinga highlights three healthcare stocks: AbbVie (3.30% yield), GSK (3.58% yield), and Bristol-Myers Squibb (4.40% yield). Analysts provide ratings and price targets, with AbbVie receiving an Overweight rating and a price target increase. GSK's stock was downgraded by Barclays but upgraded by Jefferies. Bristol-Myers Squibb announced a partnership for early-stage programs. Real-time updates are available on Benzinga's platform.

benzinga_article

Abbvie

Bristol Myers Squibb

Ark Genomic Revolution ETF

SPDR S&P Biotech

Health Care Select Sector SPDR

VG Health

ALPS Medical Breakthrough

Direxion Pharma & Medical Bull 3X

iShares US Pharma

Proshares Ultra Nasdaq Biotech

Piper Sandler Cos

Barclays

Jefferies Financial

Bank of America

Hengrui Pharma

HENGRUI PHARMA

GlaxoSmithKline plc

GSK plc Sponsored ADR

Bristol-Myers Squibb Company

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields